Compare Novavax Inc (NVAX) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs ProShares Ultra QQQ ETF — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while ProShares Ultra QQQ ETF trades at $89. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | QLD | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $11.19 | $100.53 |
52-Week Low | $6.22 | $57.16 |
Enterprise Value | $800.50M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
